Document:

EX-10.5

 Exhibit 10.5 

LICENSE AGREEMENT 

This LICENSE AGREEMENT (this “Agreement”), dated as of [•], 2017 (the “Effective Date”), is
entered into by and between Cellectis S.A., a corporation existing and registered under the laws of France, located at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”), and Calyxt, Inc., a corporation existing
and registered under the laws of Delaware, located at 600 County Road D West, Suite 8, New Brighton, MN 55112, USA (“Calyxt”) (each a “Party” and collectively, the “Parties”). 

W I T N E S S E T H: 

WHEREAS, Cellectis owns or otherwise controls certain Intellectual Property Rights and desires to grant to Calyxt, and Calyxt desires to
receive from Cellectis, a license to use and otherwise exploit such Intellectual Property Rights, in each case upon the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 

Section 1.01. Definitions. (a) For purposes of this Agreement, the following terms shall have the following
meanings: 
 “Affiliate” means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by, or under common control with such other Person, whether now or in the future. For purposes of this definition, (i) “control” when used with respect to any Person means the power to direct the
management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled” have correlative meanings
and (ii) neither Cellectis nor any of its Subsidiaries shall be considered to be an Affiliate of Calyxt or any of its Subsidiaries (and vice versa). 

“Applicable Law” means, with respect to any Person, any transnational, domestic or foreign federal, state or local law
(statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by a Governmental Authority that
is binding upon or applicable to such Person, as amended unless expressly specified otherwise. 
 “Bare
Sublicense” means any sublicense granted by Calyxt to any third party of rights to some or all of the Licensed Cellectis Patents pursuant to Section 2.03, without any Calyxt Licensed Product developed by or in collaboration with Calyxt.

  
 1 

 “Bare Sublicense Revenue” means any and all consideration, payments and
revenue (including the fair market value of any non-cash consideration) received by Calyxt pursuant to any Bare Sublicense.  

“Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in Paris, France are
authorized or required by Applicable Law to close. 
 “Calyxt Field” means the field of researching,
developing and commercializing agricultural and food products, including, but not limited to traits, seeds, proteins, oils, carbohydrates, food, and food and animal feed ingredients, excluding any application in connection with animals and animal
cells. 
 “Calyxt Improvement” means any improvements, modifications, refinements to, enhancements, derivatives or
combinations of, any Licensed Cellectis IP made by Calyxt or any of its Affiliates after the Effective Date and all Intellectual Property Rights in any of the foregoing. 

“Calyxt Improvement Patents” means any Patents owned or controlled by Calyxt or any of its Affiliates Covering any Calyxt
Improvements. 
 “Calyxt Licensed Products” means any and all products (i) the creation, generation, development,
making or use of which is, in whole or in part, Covered by a Licensed Cellectis Patent, or (ii) which is created, generated, bred or made by use of a process Covered by a Licensed Cellectis Patent. For sake of clarity, any plant or seed which
contains one or more modifications made using a process Covered by any of the Licensed Cellectis Patents, as well as any progeny of such plant or seed, any part of such plant or seed, and any product derived from such plant or seed (such as, for
example, meal and oil derived from any soybean), is a Calyxt Licensed Product. 
 “Cellectis Improvement” means any
improvements, modifications or refinements to, or enhancements or derivatives of any Licensed Cellectis IP made by Cellectis or any of its Affiliates after the Effective Date and all Intellectual Property Rights in any of the foregoing. 

“Confidential Information” means any and all non-public, proprietary or other confidential information disclosed by a
Party (“disclosing party”) to the other Party (“receiving party”) and includes all information licensed hereunder without the need for any further notice or marking, excluding any information that: (i) the
receiving party independently develops without reference to the disclosed information; (ii) the receiving party independently receives on a non-confidential and authorized basis from a source other than the disclosing party; (iii) becomes
public knowledge through no fault of the receiving party; or (iv) is in the public domain at the time the receiving party receives the disclosed information. 

“Cover” means, with respect to any product, service or process, and any Intellectual Property Right, that the
manufacture, use, offer for sale, sale, distribution, importation, development or other commercialization of such product, service or process would, but for any ownership of or license under such Intellectual Property Right, constitute an
infringement, misappropriation or other violation of any of such Intellectual Property Right. “Covered” and “Covering” have correlative meanings. 

  
 2 

 “Exclusively Licensed Cellectis Patents” means any and all Licensed
Cellectis Patents exclusively related to the Calyxt Field for which Calyxt is granted exclusive rights under the Calyxt License. 

“Governmental Authority” means any transnational, domestic or foreign federal, state or local governmental, regulatory
or administrative authority, department, court, agency or official, including any political subdivision thereof. 

“Intellectual Property Rights” means any and all intellectual property rights or similar proprietary rights throughout
the world, including all (i) national and multinational statutory invention registrations and similar statutory rights, patents and patent applications, including all provisionals, non-provisionals, divisionals, continuations,
continuations-in-part, reissues, renewals, reexaminations, extensions, supplemental protection certificates and the equivalents of any of the foregoing in any jurisdiction, and all inventions disclosed in any of the foregoing
(“Patents”); (ii) trademarks, service marks, certification marks, logos, trade names, trade dress, domain names and other indications of origin, including all registrations and applications for registration of, and all goodwill
associated with, any of the foregoing (“Trademarks”); (iii) copyrights and registrations and applications for registration thereof, including all derivative works, moral rights, renewals, extensions, reversions or restorations
associated with such copyrights, regardless of the medium of fixation or means of expression; (iv) trade secrets, know-how and other confidential or proprietary information (including processes, techniques and research and development
information); and (v) mask works, industrial designs (whether or not registered), database rights, publicity rights and privacy rights. 

“Licensable” means, with respect to any Intellectual Property Right, that a Person has the power and authority to
grant a license (or sublicense, as the case may be), on the applicable terms and conditions of this Agreement, to such Intellectual Property Right without any of the following: (i) the consent of any third party (unless such consent can be
obtained without providing any additional consideration to such third party); (ii) impairing such Person’s existing rights in respect of such Intellectual Property Right (it being understood that the grant of any license hereunder, in and
of itself, shall not be construed as an impairment of any of such Person’s rights); (iii) imposing any additional obligations on such Person under any preexisting agreement relating to such Intellectual Property Right; and/or (iv) the
payment of royalties or other consideration on or after the Effective Date by such Person to any third party under any preexisting agreement relating to such Intellectual Property Right (other than to the University of Minnesota pursuant to the
UMinn License). For the avoidance of doubt, in no event shall any Intellectual Property Right be “Licensable” if any of the foregoing conditions in clauses (i)-(iv) apply. 

“Licensed Cellectis IP” means the (i) Licensed Cellectis Patents; and (ii) Other Licensed Intellectual
Property Rights. 

  
 3 

 “Licensed Cellectis Patents” means any and all Patents that are:
(i) related to the Calyxt Field; (ii) necessary for Calyxt to operate in the Calyxt Field; and (iii) Licensable by Cellectis and existing as of the Effective Date. 

“Licensed TALEN Mark” means the trademark “TALEN” and all registrations and applications for registration
thereof, in each case as owned by Cellectis as of the Effective Date, including the registration set forth on Schedule A. 

“Net Sales” means, with respect to any Calyxt Licensed Product, the gross amount invoiced by Calyxt or any of its
sublicensees for any such Calyxt Licensed Product, in each case less (i) all trade, quantity, and cash discounts actually allowed; (ii) all credits and allowances actually granted due to rejections, returns, billing errors, and retroactive
price reductions; (iii) applicable duties; (iv) all credits or allowances given or made for uncollectible amounts and for which a provision is made in Calyxt’s financial statements; (v) the commodity price for seed and grain; and
(vi) applicable excise, sale and use taxes. Net Sales shall also include the fair market value of all other consideration received as consideration for the sale or disposition of any Calyxt Licensed Product, whether such consideration is in
cash, payment in kind, exchange or another form. Net Sales shall be determined by using generally accepted accounting principles consistently applied. 

“Non-Exclusive Field” means the field of researching, developing and commercializing a modified or mutated I-CreI homing
endonuclease that is a homodimer, heterodimer or single chain endonuclease, but solely to the extent the foregoing falls within the Calyxt Field. 

“Other Licensed Intellectual Property Rights” means any and all know-how and other Intellectual Property Rights (excluding
any Patents and Trademarks) that are (i) related to the Calyxt Field; (ii) necessary for Calyxt to operate in the Calyxt Field; and (iii) Licensable by Cellectis and existing as of the Effective Date.  

“Patent-Related Expenses” means costs and expenses (including out-of-pocket attorneys’ fees, patent agent fees and
governmental filing fees) that Cellectis or any of its Affiliates incurs in prosecuting and maintaining the Licensed Cellectis Patents which are exclusively and solely related to the Calyxt Field.  

“Person” means an individual, corporation, partnership, limited liability company, association, trust or other entity
or organization, including a Governmental Authority. 
 “Royalty Term” means, with respect to any Calyxt
Licensed Product in any jurisdiction, the period commencing on the Effective Date and ending upon the expiration of the last-to-expire Valid Claim Covering such Calyxt Licensed Product in such jurisdiction. 

“Sublicense Revenue Term” means the period commencing on the Effective Date and ending upon the expiration of the
last-to-expire Valid Claim. 

  
 4 

 “Subsidiary” means, with respect to any Person, any entity of which
securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other Persons performing similar functions are at the time directly or indirectly owned by such Person. 

“UMinn License” means the Exclusive Patent License Agreement between the University of Minnesota and Cellectis dated
as of January 10, 2011 (as amended, including by the First Amendment to the Exclusive Patent License Agreement, dated as of May 24, 2012, Second Amendment to the Exclusive Patent License Agreement, dated as of April 1, 2014, and Third
Amendment to the Exclusive Patent License Agreement, dated as of December 16, 2015). 
 “University of
Minnesota” means the Regents of the University of Minnesota. 
 “Valid Claim” means any
(i) claim in any unexpired and issued Patent included in the Licensed Cellectis Patents that has not been (A) disclaimed, revoked or held invalid or unenforceable by a decision of a court or other Governmental Authority of competent
jurisdiction from which no appeal (other than an appeal to the highest appellate court of such jurisdiction) can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, or (B) irretrievably abandoned,
disclaimed or admitted to be invalid or unenforceable by Cellectis through reissue, disclaimer or otherwise, or (ii) pending claim in a pending Patent application included in the Licensed Cellectis Patents that has not been abandoned or finally
rejected without the possibility of appeal or refiling. 
 (b) Each of the following terms is defined in the Section set forth
opposite such term: 
  

			
	 Term
	  	Section
	 Agreement
	  	Preamble
	 Calyxt
	  	Preamble
	 Calyxt License
	  	2.01
	 Calyxt TM License
	  	2.02
	 Cellectis
	  	Preamble
	 Controlling Party
	  	9.02
	 Effective Date
	  	Preamble
	 Indemnified Party
	  	8.03
	 Indemnifying Party
	  	8.03
	 Infringement
	  	9.02
	 Losses
	  	8.01
	 Necessary Third Party License
	  	5.02
	 Negotiation Period
	  	2.06
	 Non-Controlling Party
	  	9.02
	 Option Period
	  	2.06
	 Parties
	  	Preamble
	 Party
	  	Preamble
	 Remainder
	  	9.02
	 Third Party Claim
	  	8.03
	 UMinn IP
	  	2.04

  
 5 

 Section 1.02. Other Definitional and Interpretative Provisions. The words
“hereof”, “herein” and “hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for
convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Articles, Sections and Schedules are to Articles, Sections and Schedules of this Agreement unless otherwise specified. All Schedules
annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Schedule but not otherwise defined therein, shall have the meaning as defined in this
Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import. “Writing”, “written” and comparable terms refer to printing, typing and other
means of reproducing words (including electronic media) in a visible form. References to any agreement or contract are to that agreement or contract as amended, modified or supplemented from time to time in accordance with the terms hereof and
thereof. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively. References to
“law”, “laws” or to a particular statute or law shall be deemed also to include any and all Applicable Law. 

ARTICLE 2 
 GRANT
OF LICENSE 
 Section 2.01. Calyxt License. Subject to the terms and conditions of this Agreement,
Cellectis hereby grants to Calyxt an exclusive (except as otherwise provided herein and subject to existing licenses granted by Cellectis to third parties prior to the Effective Date) worldwide, perpetual license, with the right to sublicense (in
accordance with Section 2.03) under the Licensed Cellectis IP to use, have used, make, have made, sell, have sold, offer for sale, export, import and otherwise exploit any and all Calyxt Licensed Products within the Calyxt Field (the “Calyxt
License”). Notwithstanding the foregoing, the Calyxt License shall be non-exclusive solely in the Non-Exclusive Field, such that the rights as set forth above in this Section 2.01 are granted to Calyxt on a non-exclusive basis in the
Non-Exclusive Field under the Calyxt License. 
 Section 2.02. Trademark License Grant. Subject to the terms and conditions of
this Agreement, Cellectis hereby grants to Calyxt a worldwide, non-exclusive, sublicensable (in accordance with Section 2.03), royalty-free and fully paid-up, non-transferable (except as set forth in Section 11.01) license under the Licensed TALEN
Mark to use, make, have made, sell, offer for sale, import and otherwise exploit any and all Calyxt Licensed Products within the Calyxt Field (the “Calyxt TM License”). 

  
 6 

 Section 2.03. Sublicense Rights. The Calyxt License and the Calyxt TM License
include the right of Calyxt to grant sublicenses to any Person; provided that (a) any such sublicense shall be in writing and automatically terminate upon any termination of this Agreement (it being understood that any such sublicense
shall include express terms and conditions to effect such automatic termination); (b) sublicensees of the Calyxt License shall not be permitted to grant further sublicenses thereunder with respect to any UMinn IP (as defined below);
(c) Calyxt shall cause each of its sublicensees to abide by all applicable terms and conditions of this Agreement, enforce such terms and conditions and the provisions of any sublicense against each such sublicensee; and (d) Calyxt shall
remain responsible and liable to Cellectis for the performance of each such sublicensee’s obligations and for all acts or omissions of such sublicensee as if they were acts of Calyxt under this Agreement. 

Section 2.04. UMinn License. The Parties acknowledge and agree that Calyxt has received a copy of the UMinn License
and certain Licensed Cellectis IP is owned by the University of Minnesota (“UMinn IP”) and the Calyxt License with respect to the UMinn IP is granted as a sublicense under, and subject to the terms and conditions
of, the UMinn License. Accordingly, in exercising its rights under the Calyxt License, Calyxt shall comply with any and all terms and conditions of the UMinn License as they would apply to Calyxt as a sublicensee with respect to any UMinn IP.
Without limiting the generality of the foregoing, promptly following receipt of written notice thereof, Calyxt shall reimburse Cellectis for any and all payments made by Cellectis to the University of Minnesota pursuant to Sections 11.6.4 (Milestone
Payments), 11.11 (Annual Fee), and 11.12 (Commercialization Fee) of the UMinn License, but solely to the extent that any such payments are required as a result of the applicable activities of Calyxt hereunder or thereunder. Calyxt shall not be
liable to the University of Minnesota for any other payments other than those as specifically set forth in the previous sentence. Without the prior written consent of Calyxt, Cellectis shall not (A) terminate the UMinn License, or
(B) amend or waive any rights under the UMinn License in any manner that would reasonably be expected to have a material adverse effect on any of Calyxt’s rights under this Agreement. In addition, Calyxt shall provide, and shall cause its
sublicensees to provide, to Cellectis all reports, information and other assistance in connection with Calyxt’s and its sublicensees’ activities pursuant to this Agreement that are reasonably required to enable Calyxt to comply with its
obligations under the UMinn License.  
 Section 2.05. Calyxt Improvements. (a) As between the Parties, any
and all Calyxt Improvements shall be solely and exclusively owned by Calyxt. 
 (b) Subject to the terms and conditions of this
Agreement, Calyxt, on behalf of itself and its Affiliates, hereby grants to Cellectis and its Affiliates an exclusive, perpetual, worldwide, sublicensable, non-transferable (except as set forth in Section 11.01), royalty-free and fully paid-up
license to use and otherwise exploit Calyxt Improvements for any purpose outside of the Calyxt Field. On a continuing basis during the term of this Agreement, Calyxt shall promptly make available to Cellectis all Calyxt Improvements then in
existence that are necessary or reasonably useful for the commercialization of such Calyxt Improvements by Cellectis outside of the Calyxt Field, and provide Cellectis with all reasonable assistance to enable Cellectis to understand and use such
Calyxt Improvement. Calyxt shall use commercially reasonable efforts to identify and disclose all Calyxt Improvements based on facts known to Calyxt, as well as in response to specific requests made by Cellectis. 

  
 7 

 Section 2.06. Calyxt Option on Cellectis Improvements. Solely during the
period in which Cellectis and its Affiliates own, in the aggregate, a number of Calyxt common shares equal to at least fifty percent (50%) of the then outstanding common shares of Calyxt, Cellectis shall promptly disclose to Calyxt all
Cellectis Improvements then in existence that are necessary or reasonably useful for the commercialization of such Cellectis Improvements by Calyxt in the Calyxt Field, and provide Calyxt an option to obtain a license within the Calyxt Field. Calyxt
may exercise its option by sending a written notice to Cellectis within thirty (30) days after it has the knowledge of such Cellectis Improvements (the “Option Period”). If Calyxt has exercised its option within
the Option Period to obtain such a license, then for a period of thirty (30) days after Cellectis receives such notice from Calyxt (the “Negotiation Period”), the Parties shall, in good faith, negotiate the terms
and conditions of a definitive agreement pursuant to which Cellectis would grant Calyxt a royalty-bearing license with respect to such Cellectis Improvement; provided that if Calyxt does not exercise its option within the Option Period, or if
the Parties do not agree on the terms and conditions of such a definitive agreement for such license within the Negotiation Period, Cellectis shall be free to grant any third party any license or other rights with respect to such Cellectis
Improvement. 
 Section 2.07. No Other Licenses. Except as expressly provided in this Agreement, no other licenses
are granted to either Party under this Agreement. Each Party acknowledges and agrees that (a) any use by Calyxt or any of its sublicensees of the Licensed Cellectis IP outside the scope of the Calyxt License or the Licensed TALEN Mark outside
the scope of the Calyxt TM License is expressly prohibited and (b) any use by Cellectis or any of its sublicensees of the Calyxt Improvements outside the scope of the licenses granted to Cellectis or any of its sublicensees pursuant to Section
2.05 is expressly prohibited. 
 ARTICLE 3 

LICENSED TALEN MARK; QUALITY CONTROL 

Section 3.01. Quality Control. Cellectis reserves the right to practice reasonable quality control with regard to the use
of the Licensed TALEN Mark by Calyxt or any of its sublicensees and Calyxt shall, and shall cause its sublicensees to, adhere to such quality, appearance, reputational, distinctiveness and other standards with respect to the use of the Licensed
TALEN Mark and with respect to the goods and services sold or rendered under the Licensed TALEN Mark as Cellectis may require from time to time. Calyxt hereby acknowledges the validity of the Licensed TALEN Mark and Cellectis’ exclusive right,
title, and interest in and to the Licensed TALEN Mark, subject to the license granted hereunder. Calyxt shall, and shall cause its sublicensees to, (a) not take any action or make any statement which would reasonably be expected to damage the
reputation or goodwill associated with Cellectis, any of its Affiliates, or the Licensed TALEN Mark, or to prejudice, infringe or impair the rights of Cellectis with respect to the Licensed TALEN Mark and (b) comply with all Applicable Law
governing the use of the Licensed TALEN Mark, including all services performed under the Licensed TALEN Mark and all goods to which the Licensed TALEN Mark is applied. At Calyxt’s sole expense, Calyxt shall supply, and shall cause its
sublicensees to supply, Cellectis with specimens of all uses of the Licensed TALEN Mark upon the reasonable request of Cellectis. 

  
 8 

 Section 3.02. Reservation of Rights; Ownership. (a) Calyxt, on behalf of itself
and its sublicensees, acknowledges and agrees that (i) Cellectis is the sole and exclusive owner of all right, title and interest in and to the Licensed TALEN Mark; (ii) Cellectis shall have the sole and exclusive right to prosecute and
maintain the Licensed TALEN Mark; and (iii) neither Calyxt nor any of its sublicensees has acquired, and shall not acquire, any right, title or interest in or to the Licensed TALEN Mark other than the rights expressly set forth in this
Agreement. Calyxt shall cooperate with Cellectis in taking all appropriate measures for the protection of the Licensed TALEN Mark. 
 (b)
Calyxt shall not, and shall cause its sublicensees not to, (i) challenge the validity, enforceability or ownership of the Licensed TALEN Mark or claim adversely or assist in any claim adverse to Cellectis concerning any right, title or interest
in the Licensed TALEN Mark; (ii) do or permit any act which may directly or indirectly impair or prejudice Cellectis’ title to the Licensed TALEN Mark or be detrimental to the reputation and goodwill of Cellectis or any of its Affiliates,
including any act which might assist or give rise to any application to remove or de-register any of the Licensed TALEN Mark; or (iii) register or attempt to register any trademarks for any words, names, graphics, or other source identifiers
that are identical or confusingly similar to the Licensed TALEN Mark. All use of the Licensed TALEN Mark by Calyxt and any of its sublicensees, and all goodwill associated with such use, shall inure to the benefit of Cellectis. 

Section 3.03. Trademark Notice. In connection with the use of the Licensed TALEN Mark, Calyxt and its sublicensees shall
mark each use with the registered trademark symbol, “®,” or such other trademark notice symbol as designated by Cellectis. 

ARTICLE 4 
 COMMERCIALIZATION 

Section 4.01 Commercialization and Performance Milestones. Calyxt shall use its commercially reasonable efforts, and shall
require all sublicensees to use commercially reasonable efforts, in each case consistent with sound and reasonable business practices and judgment, to commercialize the Licensed Cellectis Patents in the Calyxt Field and to manufacture, offer to sell
and sell Calyxt Licensed Products as soon as practicable and to maximize sales thereof.  
 Section 4.02 Covenants
Regarding the Manufacture of Licensed Products. Calyxt hereby covenants and agrees, and shall require all sublicensees to covenant and agree, that (a) the manufacture, use, sale, or transfer of Calyxt Licensed Products shall comply with all
Applicable Laws, including all federal export laws and regulations; and (b) it will make commercially reasonable efforts such that the Calyxt Licensed Products shall not be defective in design or manufacture. Calyxt hereby further covenants and
agrees that, pursuant to 35 United States Code Section 204, it shall, and it shall cause each sublicensee, to substantially manufacture in the United States of America all products embodying or produced through the use of an invention
that is subject to the rights of the federal government of the United States of America. 

  
 9 

 Section 4.03 Export and Regulatory Compliance. Calyxt understands that the
Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR) and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and
regulations that comprise the U.S. export laws and regulations. Calyxt further understands that the U.S. export laws and regulations include (but are not limited to): (i) ITAR and EAR product/service/data-specific requirements; (ii) ITAR
and EAR ultimate destination-specific requirements; (iii) LIAR and EAR end user-specific requirements; (iv) Foreign Corrupt Practices Act; and (v) antiboycott laws and regulations. Calyxt shall comply with all then-current applicable
export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Calyxt Licensed Products (including any associated products, items, articles, computer software, media, services, technical data,
and other information). Calyxt certifies that it shall not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Calyxt Licensed Products (including any associated products, items,
articles, computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations. Calyxt shall include an appropriate provision in its agreements with
its authorized sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations. 

Section 4.04 Commercialization Reports. As requested by Cellectis in writing, no more than once per year, Calyxt shall
deliver to Cellectis written reports of Calyxt’s and its sublicensees’ efforts and plans to commercialize the Licensed Cellectis Patents in the Calyxt Field and to manufacture, offer to sell, or sell Calyxt Licensed Products. 

Section 4.05 Use of Cellectis and University of Minnesota Names and Trademarks. Except for the Licensed TALEN Mark, no
provision of this Agreement grants Calyxt or any of its sublicensees any right or license to use the name, logo, or any marks owned by or associated with Cellectis, the University of Minnesota or the names, or identities of any member of the
faculty, staff, or student body of the University of Minnesota. Calyxt shall not use and shall not permit any of its sublicensees to use any such logos, marks, names, or identities without the prior written approval of Cellectis or the University of
Minnesota, as applicable. 
 Section 4.06 Governmental Markings. 

(a) Calyxt and its sublicensees may mark all Calyxt Licensed Products in a manner consistent with their current patent marking practices for
their own products and Applicable Laws. Where marking is to be performed but the Calyxt Licensed Product cannot be marked, the patent notice shall be placed on associated tags, labels, packaging, or accompanying documentation (either electronic or
paper) as appropriate. 

  
 10 

 (b) Calyxt and its sublicensees are solely responsible for obtaining all necessary approvals from
Governmental Authorities for the development, production, distribution, sale, and use of any Calyxt Licensed Product, at Calyxt’s expense, including, without limitation, any safety studies. Calyxt is solely responsible for including with the
Calyxt Licensed Product any warning labels, packaging and instructions as to the use and the quality control for such Calyxt Licensed Product. 

(c) Calyxt agrees to register this Agreement with any foreign Governmental Authority that requires such registration, and Calyxt shall pay all
costs and legal fees in connection with such registration. Calyxt shall comply with all foreign laws affecting this Agreement or the sale of Calyxt Licensed Products. 

ARTICLE 5 

ROYALTIES AND BARE SUBLICENSE REVENUE 

Section 5.01. Royalties and Bare Sublicense Revenue. As consideration for the Calyxt License, Calyxt shall pay to Cellectis the
following amounts during the following periods: 
 (a) With respect to each Calyxt Licensed Product in any jurisdiction, three percent
(3%) of all Net Sales of such Calyxt Licensed Product in such jurisdiction during the Royalty Term for such Calyxt Licensed Product; and 

(b) thirty percent (30%) of all Bare Sublicense Revenue during the Sublicense Revenue Term. 

Section 5.02. Royalty Stacking for Third Party Rights. (a) If Calyxt is presently required, or in the future is
required, to secure a royalty-bearing or fee-bearing license under any patent to use, make, have made, sell, offer for sale or import any Calyxt Licensed Product in the Calyxt Field in any jurisdiction (a “Necessary Third Party
License”), then, during the period in which Calyxt is required to make royalty payments to the licensor under such Necessary Third Party License, Calyxt shall have the right to reduce the royalty rate contemplated in Section 5.01(a)
with respect to the Net Sales of such Calyxt Licensed Product in such jurisdiction by an amount equal to one quarter (1/4) of the royalty rate payable to such licensor pursuant to such Necessary Third Party License; provided that, in no
event shall the royalty rate contemplated in Section 5.01(a) with respect to any Net Sales of any Calyxt Licensed Product be reduced to less than two percent (2%). If such Necessary Third Party License includes a royalty stacking provision of like
intent to this Section 5.02, the royalty rate reduction provided for in this Section 5.02 will be calculated as if such provision in such Necessary Third Party License were absent. For the avoidance of doubt, and notwithstanding anything in this
Agreement to the contrary, in no event shall any agreement to which Calyxt is a party as of or prior to the Effective Date be deemed a Necessary Third Party License under this Agreement.  

  
 11 

 (b) Without limiting Section 5.02(a), and by way of example only: 

(i) If, after the Effective Date, Calyxt is required to enter into a Necessary Third Party License, pursuant to which Calyxt is
required to pay the licensor thereunder a royalty of two percent (2%) of the net sales of a Calyxt Licensed Product in a jurisdiction, then, during the period in which such royalty is required to be paid, the royalty rate contemplated in
Section 5.01(a) with respect to the Net Sales of such Calyxt Licensed Product in such jurisdiction would equal two and one half percent (2.5%). 

(ii) If, after the Effective Date, Calyxt is required to enter into a Necessary Third Party License, pursuant to which Calyxt
is required to pay the licensor thereunder a royalty of eight percent (8%) of the net sales of a Calyxt Licensed Product in a jurisdiction, then, during the period in which such royalty is required to be paid, the royalty rate contemplated in
Section 5.01(a) with respect to the Net Sales of such Calyxt Licensed Product in such jurisdiction would equal two percent (2%). 

Section 5.03. Reimbursement of Patent-Related Expenses. Commencing on the Effective Date, Calyxt shall pay all invoices
issued by Cellectis or any of its Affiliates for any Patent-Related Expenses under this Agreement within thirty (30) days of its receipt of each such invoice.  

Section 5.04. Reporting; Audit Rights. Calyxt shall render to Cellectis, on a calendar quarterly basis, commencing with the first
calendar quarter after the Effective Date, a detailed written report of the royalties and Bare Sublicense Revenue due to Cellectis. Such report shall be accompanied by a remittance of such royalties and Bare Sublicense Revenue as shown to be due
hereunder. Each report shall be rendered within thirty (30) days following the end of each calendar quarterly period. Calyxt shall keep books and records in sufficient detail to enable the royalty payments and Bare Sublicense Revenue due
hereunder to be adequately determined. Once per calendar year, upon reasonable written notice, Cellectis or any third party owner of Patent rights included in the Licensed Cellectis IP shall have the right at its sole cost and expense to cause a
nationally recognized independent certified public accountant reasonably acceptable to Calyxt to examine and inspect such books and records during Calyxt’s normal business hours, but only to the extent necessary to verify the computation of
royalties and Bare Sublicense Revenue payable hereunder. Such books and records shall be deemed Confidential Information of Calyxt hereunder, and such nationally recognized independent certified public accountant shall disclose to Cellectis or such
third party only the royalties and Bare Sublicense Revenue payable and the percentage under/overpayment by Calyxt. In the event that such examination determines that Calyxt has underpaid royalties and Bare Sublicense Revenue by more than three
percent (3%), Calyxt shall reimburse Cellectis for its reasonable costs in conducting such examination. At Calyxt’s expense, Calyxt shall also provide Cellectis with all reasonably requested cooperation in connection with complying with any
audit regarding the activities of Calyxt hereunder that is conducted by or on behalf of the University of Minnesota pursuant to the UMinn License. 

Section 5.05. Method of Payment. Each payment by Calyxt hereunder shall be made by electronic transfer in immediately
available funds, at Cellectis’ election, via either a bank wire transfer or any other means of electronic funds transfer to a bank account specified in writing by Cellectis to Calyxt. Cellectis may change such account by written notice at least
five (5) Business Days before any payment is due. All royalties and Bare Sublicense Revenue of Calyxt  

  
 12 

 
shall be computed and paid in U.S. dollars. For the purposes of determining the amount of any royalties or Bare Sublicense Revenue due for any relevant calendar quarter, the amount of Net Sales
or Bare Sublicense Revenue in any foreign currency shall be converted into U.S. dollars in a manner consistent with Calyxt’s customary practices used to prepare its audited financial reports. No more than once per calendar year, upon written
request of Cellectis, Calyxt shall provide Cellectis with a written explanation of such customary practices of Calyxt. 

Section 5.06. Withholding Taxes. To the extent either Party is required by Applicable Law to withhold or deduct any amounts
from any payments to be made under this Agreement, such Party shall be entitled to withhold or deduct such amounts and such amounts shall be treated for all purposes of this Agreement as having been paid to the Party in respect of which such
deduction and withholding were made. Each Party shall (in consultation and cooperation with the other) use commercially reasonable efforts to attempt to lawfully mitigate, reduce or avoid such withholdings or deductions. Promptly after the execution
of this Agreement, Cellectis shall provide to Calyxt a valid Form W-8BEN-E establishing Cellectis’ right to a zero percent rate of withholding tax with respect to the amounts payable by Calyxt under this Article 5 under Article 12 of the United
States – France income tax treaty. 
 ARTICLE 6 

REPRESENTATIONS AND WARRANTIES; 

DISCLAIMERS; LIMITATION OF LIABILITY 

Section 6.01. Mutual Representations and Warranties. As of the Effective Date, each Party hereby represents and warrants to
the other Party that (a) the execution, delivery and performance by such Party of this Agreement are within such Party’s corporate powers and have been duly authorized by all necessary corporate action on the part of such Party and
(b) this Agreement constitutes a valid and binding agreement of such Party enforceable against such Party in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws
affecting creditors’ rights generally and general principles of equity). 
 Section 6.02. Disclaimers and Limitation of
Liability. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES IN SECTION 6.01, ALL LICENSES AND RIGHTS GRANTED HEREIN ARE MADE ON AN “AS IS” BASIS, AND THE PARTIES EACH HEREBY DISCLAIM ANY EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES OF
ANY KIND, INCLUDING WITHOUT LIMITATION, THOSE REGARDING MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, CALYXT ACKNOWLEDGES AND AGREES THAT ALL RIGHTS GRANTED TO
CALYXT UNDER THIS AGREEMENT ARE SUBJECT IN ALL RESPECTS TO ANY AND ALL LICENSES OR OTHER RIGHTS GRANTED BY CELLECTIS OR ANY OF ITS AFFILIATES TO ANY THIRD PARTIES WITH RESPECT TO ANY LICENSED CELLECTIS IP AS OF OR PRIOR TO THE EFFECTIVE DATE. TO THE
EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY SHALL BE LIABLE UNDER 

  
 13 

 
ANY LEGAL OR EQUITABLE THEORY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR OTHERWISE RELATED TO THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 Section 6.03. University of Minnesota Disclaimer; Limitation of Liability; and
Release. 
 (a) Calyxt acknowledges and agrees that the disclaimer, remedy limitation and damages cap provisions applicable to and
exclusion of representations and warranties by the University Minnesota, set forth in Sections 10.2, 11.1 and 11.2 of the UMinn License shall apply with respect to Calyxt’s rights and remedies under this Agreement and such Sections are hereby
incorporated by reference herein, mutatis mutandis. 
 (b) Calyxt, on behalf of itself and its Affiliates and its and their respective
employees, hereby releases the University of Minnesota, Cellectis and their respective regents, employees and agents forever from any and all suits, actions, claims, liabilities, demands, damages, losses, and expenses (including reasonable
attorneys’ and investigative expenses) relating to or arising out of the manufacture, use, lease, sale, or other disposition of any Calyxt Licensed Product. 

ARTICLE 7 

CONFIDENTIALITY 

Section 7.01. Confidentiality. (a) The receiving party shall keep confidential the disclosing party’s
Confidential Information, and shall not use any of the disclosing party’s Confidential Information for any purpose other than the exercise of the receiving party’s rights, or as otherwise permitted, under this Agreement. The receiving
party shall preserve the confidentiality of the disclosing party’s Confidential Information as it would customarily take to preserve the confidentiality of its own similar type of confidential information and shall not disclose the disclosing
party’s Confidential Information to any third party without the prior written consent of the disclosing party, except as expressly permitted hereunder. The receiving party may disclose the Confidential Information to (i) any of its
employees, agents, independent contractors and sublicensees who need it in connection with this Agreement and are bound in writing by restrictions regarding disclosure and use of the Confidential Information comparable to and no less restrictive
than those set forth herein or (ii) the extent it is in response to a valid order of a court or other Governmental Authority or to otherwise comply with Applicable Law; provided that, in the case of clause (ii), the receiving party shall
first provide written notice to the disclosing party and reasonably cooperate with the disclosing party to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the
information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by Applicable Law. 

(b) The terms and conditions of this Agreement shall be deemed Confidential Information for the purposes of this Agreement;
provided that each Party may disclose the terms and conditions of this Agreement: (i) in confidence, to its accountants, banks and present and prospective financing sources and their advisors; (ii) in connection with the enforcement
of this Agreement or rights under  

  
 14 

 
this Agreement; (iii) in confidence, in connection with an actual or proposed merger, acquisition or similar transaction involving such Party; (iv) in confidence, to its Affiliates;
(v) in confidence, to its third party independent contractors who have a need to know, solely in connection with their provision of services to such Party; (vi) as required by applicable securities laws or the rules of any stock exchange
on which securities of such Party are traded or any other Applicable Law; or (vii) as mutually agreed upon by the Parties in writing. 

ARTICLE 8 

INDEMNIFICATION 

Section 8.01. Indemnification by Calyxt. Calyxt shall defend Cellectis and its Affiliates and their respective officers,
directors, employees, contractors, customers and agents against any action, suit, proceeding or other claim, and indemnify and hold each of them harmless from any and all damages, liabilities, expenses, and other losses (including reasonable
attorneys’ fees and court costs) (“Losses”) to the extent arising from any (a) breach of this Agreement by Calyxt; (b) breach of the UMinn License caused by any activities of Calyxt or its sublicensees;
(c) use, making, having made, sale, offer for sale, importation or any other exploitation of any Calyxt Licensed Products or any exploitation of the Licensed Cellectis IP by Calyxt or any of its sublicensees; (d) gross negligence or
willful misconduct by Calyxt; and/or (e) violation of Applicable Law by Calyxt. 
 Section 8.02. Indemnification
by Cellectis. Cellectis shall defend Calyxt and its Affiliates and their respective officers, directors, employees, and agents against any action, suit, proceeding or other claim, and indemnify and hold each of them harmless from any and all
Losses to the extent arising from any (a) breach of this Agreement by Cellectis; (b) gross negligence or willful misconduct by Cellectis; and/or (c) violation of Applicable Law by Cellectis. 

Section 8.03. Third Party Claim Procedures. (a) The Party seeking indemnification under Section 8.01 or 8.02 (the
“Indemnified Party”) shall give prompt notice in writing to the Party against whom indemnity is to be sought (the “Indemnifying Party”) of the assertion of any claim or the commencement
of any action, suit, proceeding or other claim by any third party (“Third Party Claim”) in respect of which indemnity may be sought under such Section. Such notice shall set forth in reasonable detail such Third Party
Claim and the basis for indemnification (taking into account the information then available to the Indemnified Party). The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder, except to
the extent such failure shall have actually prejudiced the Indemnifying Party.  
 (b) The Indemnifying Party shall be entitled
to participate in the defense of any Third Party Claim and, subject to the limitations set forth in this Section, shall be entitled to control and appoint lead counsel for such defense, in each case at its own expense; provided that prior to
assuming control of such defense, the Indemnifying Party must acknowledge that it would have an indemnity obligation for the Losses resulting from such Third Party Claim as provided under this Article 8. 

  
 15 

 (c) The Indemnifying Party shall not be entitled to assume or maintain control of the defense of
any Third Party Claim and shall pay the fees and expenses of counsel retained by the Indemnified Party if (i) the Indemnifying Party does not deliver the acknowledgment referred to in Section 8.03(b) within thirty (30) days of receipt of
notice of the Third Party Claim pursuant to Section 8.03(a); (ii) the Third Party Claim relates to or arises in connection with any criminal action, proceeding or claim; (iii) the Third Party Claim seeks an injunction or equitable relief
against the Indemnified Party or any of its Affiliates; or (iv) the Indemnifying Party has failed or is failing to prosecute or defend vigorously the Third Party Claim. 

(d) If the Indemnifying Party shall assume the control of the defense of any Third Party Claim in accordance with the provisions of this
Section 8.03, the Indemnifying Party shall obtain the prior written consent of the Indemnified Party before entering into any settlement of such Third Party Claim. 

(e) In circumstances where the Indemnifying Party is controlling the defense of a Third Party Claim in accordance with paragraphs
(b) and (c) above, the Indemnified Party shall be entitled to participate in the defense of any Third Party Claim and to employ separate counsel of its choice for such purpose, in which case the fees and expenses of such separate counsel
shall be borne by the Indemnified Party; provided that in such event the Indemnifying Party shall pay the fees and expenses of such separate counsel (i) incurred by the Indemnified Party prior to the date the Indemnifying Party assumes
control of the defense of the Third Party Claim or (ii) if representation of both the Indemnifying Party and the Indemnified Party by the same counsel would create a conflict of interest. 

(f) Each Party shall cooperate, and cause their respective Affiliates to cooperate, in the defense or prosecution of any Third Party Claim and
shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection therewith. 

Section 8.04. Direct Claim Procedures. In the event that an Indemnified Party has a claim for indemnity under Section 8.01
or 8.02 against an Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party shall give prompt notice in writing of such claim to the Indemnifying Party. Such notice shall set forth in reasonable detail such claim and the
basis for indemnification (taking into account the information then available to the Indemnified Party). The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder, except to the extent such
failure shall have actually prejudiced the Indemnifying Party. 
 ARTICLE 9 

PROSECUTION, MAINTENANCE; LITIGATION 

Section 9.01. Prosecution and Maintenance. (a) As between the Parties, Cellectis shall have the sole and exclusive right to
prosecute and maintain the Licensed Cellectis IP and Licensed TALEN Mark (it being understood that, and Calyxt acknowledges and agrees that, pursuant to the UMinn License, the University of Minnesota has the sole and exclusive right to

  
 16 

 
prosecute and maintain the UMinn IP). Subject to any rights granted to any third parties prior to the date hereof with respect to any Exclusively Licensed Cellectis Patents, Cellectis shall
(i) keep Calyxt reasonably informed of all steps to be taken in connection with the prosecution and maintenance of the Exclusively Licensed Cellectis Patents, and (ii) consider in good faith (or, in the case of any Exclusively Licensed
Cellectis Patents being prosecuted by the University of Minnesota, use commercially reasonable efforts to cause the University of Minnesota to consider in good faith) all reasonable comments and suggestions by Calyxt regarding such matters,
including in respect of any actions, decisions, applications, amendments, submissions or correspondence related thereto. Notwithstanding the foregoing, subject to any rights granted to any third parties prior to the date hereof with respect to any
Exclusively Licensed Cellectis Patents, in the event that Cellectis elects to abandon or otherwise cease prosecuting and maintaining any Exclusively Licensed Cellectis Patent (excluding the Patents licensed to Cellectis under the UMinn License),
prior to any such abandonment, Calyxt shall have the option to acquire at no cost any such Exclusively Licensed Cellectis Patent and assume the responsibility for the prosecution and maintenance of such Exclusively Licensed Cellectis Patent (it
being understood that, in the event that Calyxt exercises such option to acquire such Exclusively Licensed Cellectis Patent, (A) Cellectis shall execute and deliver any documents and perform any other acts, in each case as may be reasonably
necessary to effect the foregoing and (B) effective as of Calyxt acquiring ownership of such Exclusively Licensed Cellectis Patent, such Exclusively Licensed Cellectis Patent shall thereafter be automatically deemed to be licensed to Cellectis
under the licenses granted to Cellectis pursuant to Section 2.05). 
 (b) As between the Parties, Calyxt shall have the sole and exclusive
right to prosecute and maintain all Intellectual Property Rights owned or otherwise controlled by Calyxt or any of its Affiliates, including all Intellectual Property Rights in or to any Calyxt Improvements. To the extent that any Calyxt Improvement
Patents relate to any subject matter outside of the Calyxt Field, Calyxt shall (i) keep Cellectis reasonably informed of all steps to be taken in connection with the prosecution and maintenance of such Calyxt Improvement Patents, and
(ii) consider in good faith all reasonable comments and suggestions by Cellectis regarding such matters, including in respect of any actions, decisions, applications, amendments, submissions or correspondence related thereto. Notwithstanding
the foregoing, in the event that Calyxt elects to abandon or otherwise cease prosecuting or maintaining any such Calyxt Improvement Patent related to any subject matter outside of the Calyxt Field, prior to any such abandonment, Cellectis shall have
the option to acquire at no cost any such Calyxt Improvement Patent and assume the responsibility for the prosecution and maintenance of such Calyxt Improvement Patent (it being understood that, in the event that Cellectis exercises such option to
acquire such Calyxt Improvement Patent, (x) Calyxt shall execute and deliver any documents and perform any other acts, in each case as may be reasonably necessary to effect the foregoing and (y) effective as of Cellectis acquiring
ownership of such Calyxt Improvement Patent, such Calyxt Improvement Patent shall thereafter be automatically deemed to be licensed to Calyxt under the Calyxt License). 

Section 9.02. Litigation. (a) If either Party becomes aware of any actual or threatened infringement or other violation by
any third party of any Licensed Cellectis Patent or Calyxt Improvement Patent, or any challenge to any Licensed Cellectis Patent or Calyxt Improvement Patent by any third party, then such Party shall promptly notify the other Party in writing
thereof. 

  
 17 

 (b) Cellectis shall have the first right, but not the obligation, at its expense and using
counsel of its choice, to enforce any Licensed Cellectis Patent against any Person or defend any challenge with respect to any such Licensed Cellectis Patent. Cellectis shall have sole and exclusive control of any decisions or other aspects of any
such enforcement or defense; provided that if Cellectis elects to not (i) enforce any Exclusively Licensed Cellectis Patent against any infringement or other violation of the exclusive rights granted to Calyxt under the Calyxt License or
(ii) defend any such Exclusively Licensed Cellectis Patent from any challenge that would be reasonably expected to have a material adverse effect on Calyxt’s exclusive rights under the Calyxt License, then in either case (but only to the
extent that prior to the date hereof Cellectis has not granted any third party any right to enforce or defend any such Exclusively Licensed Cellectis Patent), Cellectis shall promptly provide Calyxt with written notice of such election and,
following receipt of such notice, Calyxt may, at its sole option and expense, enforce its rights under or defend any challenge to such Exclusively Licensed Cellectis Patent, as applicable. 

(c) Calyxt shall have the first right, but not the obligation, at its expense and using counsel of its choice, to enforce any Calyxt
Improvement Patent against any Person or defend any challenge with respect to any such Calyxt Improvement Patent. Calyxt shall have sole and exclusive control of any decisions or other aspects of any such enforcement or defense; provided that
if Calyxt elects to not (i) enforce any such Calyxt Improvement Patent against any infringement or other violation thereof outside of the Calyxt Field or (ii) defend any such Calyxt Improvement Patent from any challenge that would be
reasonably expected to have a material adverse effect on Cellectis’ rights under the licenses granted to Cellectis pursuant to Section 2.05, then in either case, Calyxt shall promptly provide Cellectis with written notice of such election
and, following receipt of such notice, Cellectis may, at its sole option and expense, enforce its rights under or defend any challenge to such Calyxt Improvement Patent, as applicable. 

(d) The Party controlling any enforcement or defense under Section 9.02(b) or 9.02(c) (the “Controlling
Party”) shall keep the other Party (the “Non-Controlling Party”) reasonably and regularly informed of the status and progress of such enforcement or defense efforts, and shall reasonably consider the
Non-Controlling Party’s comments on any such efforts. The Non-Controlling Party shall provide the Controlling Party with all reasonable assistance in the enforcement or defense of any Exclusively Licensed Cellectis Patents or Calyxt Improvement
Patents, as applicable, as the Controlling Party may reasonably request, including by signing or executing any necessary documents and consenting to it being named a party to any applicable proceedings. The Non-Controlling Party shall have the right
to be represented in any enforcement or defense of any Exclusively Licensed Cellectis Patents or Calyxt Improvement Patents, as applicable, by counsel of its choice and at its own expense. Neither Party shall settle any action, suit, proceeding or
other claim involving any Exclusively Licensed Cellectis Patent or Calyxt Improvement Patent in any manner without the prior written consent of the other Party, such consent not to be unreasonably withheld. 

  
 18 

 (e) Any recoveries resulting from an action, suit, proceeding or other claim brought by a
Party under Section 9.02(b) or 9.02(c) shall be first applied against payment of each Party’s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses (the “Remainder”)
shall be retained by the Controlling Party; provided that if Calyxt is the Controlling Party, the Remainder with respect to any enforcement of the Exclusively Licensed Cellectis Patents shall be included in Net Sales and Bare Sublicense
Revenue, as applicable, for purposes of calculating royalties and payments owed to Cellectis hereunder. 
 (f) For the avoidance of
doubt, as between the Parties, (i) Cellectis shall have the sole and exclusive right, but not the obligation, to bring and control any legal action in connection with any actual, alleged, or threatened infringement of any Licensed Cellectis
Patents (A) outside of the Calyxt Field and (B) within the Non-Exclusive Field, in each case at Cellectis’ own expense as it reasonably determines appropriate and (ii) Calyxt shall have the sole and exclusive right, but not the
obligation, to bring and control any legal action in connection with any actual, alleged, or threatened infringement of any Calyxt Improvement Patents within the Calyxt Field at its own expense as it reasonably determines appropriate. 

ARTICLE 10 
 TERM
AND TERMINATION 
 Section 10.01. Term. This Agreement shall remain in full force and effect in
perpetuity unless earlier terminated, in whole or in part, pursuant to Section 10.02 or 10.03. 
 Section 10.02. Mutual
Agreement. This Agreement may be terminated in its entirety at any time upon the mutual written agreement of the Parties. 

Section 10.03. For Cause. Either Party may, by written notice to the other Party, immediately terminate this Agreement
(a) if such other Party is in material breach of any provision of this Agreement (it being understood that if such breach is capable of being cured, such other Party shall have the right to cure such breach within sixty (60) days of
receiving written notice thereof) and (b) upon the bankruptcy, dissolution or winding up of such other Party, or the making or seeking to make or arrange an assignment for the benefit of creditors of such other Party, or the initiation of
proceedings in voluntary or involuntary bankruptcy, or the appointment of a receiver or trustee of such other Party’s property that is not discharged within ninety (90) days. 

Section 10.04. Survival. Notwithstanding anything in this Agreement to the contrary, Sections 2.05(a), 2.07, 3.02, 5.04,
6.02, 6.03, 9.02(f) and 10.04, and Articles 7, 8 and 11 shall survive any expiration or termination of this Agreement. 

  
 19 

 ARTICLE 11 

MISCELLANEOUS 

Section 11.01. Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise
transferred by either Party, in whole or in part, whether voluntarily or by operation of Applicable Law, without the prior written consent of the other Party; provided that either Party may, without the consent of the other Party, assign or
otherwise transfer this Agreement to (a) any of its Affiliates or (b) any successor to all or substantially all of the assets or business of such Party to which this Agreement relates. Any attempted assignment or transfer in contravention
of this Section 11.01 shall be void ab initio. 
 Section 11.02. Notices. All notices, requests and other
communications to either Party hereunder shall be in writing (including facsimile transmission and electronic mail transmission, so long as a receipt of such electronic mail is requested and received) and shall be given, 

if to Cellectis, to: 
 Cellectis
S.A. 
 8 rue de la Croix Jarry 

75013 Paris, France 
 Attention:
Marie-Bleuenn Terrier 
 E-mail: marie-bleuenn.terrier@cellectis.com 

if to Calyxt, to: 
 Calyxt, Inc.

 600 County Road D West, Suite 8 

New Brighton, MN 55112 

Attention: Federico A. Tripodi 

E-mail: Federico.tripodi@calyxt.com 
 or such
other address or facsimile number as such Party may hereafter specify for the purpose by notice to the other Party. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if
received prior to 5:00 p.m. in the place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such notice, request or communication shall be deemed not to have been received until the next succeeding Business Day in the
place of receipt. 
 Section 11.03. Amendments and Waivers. (a) Any provision of this Agreement may be amended or
waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each Party, or in the case of a waiver, by the Party against whom the waiver is to be effective. 

(b) No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any
single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies
provided by Applicable Law. 

  
 20 

 Section 11.04. Expenses. Except as otherwise provided herein, all costs and
expenses incurred in connection with this Agreement shall be paid by the Party incurring such cost or expense. 

Section 11.05. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of France

 Section 11.06. Jurisdiction. The Parties agree that any suit, action or proceeding seeking to enforce any
provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought in a court of competent jurisdiction sitting in Paris, France and each of the Parties hereby
irrevocably consents to the exclusive jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now
or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Process in any such suit, action
or proceeding may be served on any Party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each Party agrees that service of process on such Party as provided in Section 11.02 shall
be deemed effective service of process on such Party. 
 Section 11.07. WAIVER OF JURY TRIAL. EACH OF THE PARTIES
HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

Section 11.08. Counterparts; Effectiveness; Third Party Beneficiaries. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party shall have received a counterpart hereof signed by
the other Parties. Until and unless each Party has received a counterpart hereof signed by the other Party, this Agreement shall have no effect and neither Party shall have any right or obligation hereunder (whether by virtue of any other oral or
written agreement or other communication). No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations, or liabilities hereunder upon any Person other than the Parties and their respective successors and assigns;
provided that the University of Minnesota shall be a third party beneficiary of Section 6.03. 
 Section 11.09.
Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings, both oral and written, between the Parties
with respect to the subject matter hereof and thereof. 

  
 21 

 Section 11.10. Relationship of the Parties. Nothing contained in this Agreement is
intended or shall be deemed to make either Party the agent, employee, partner or joint venturer of the other Party or be deemed to provide such Party with the power or authority to act on behalf of the other Party or to bind the other Party to any
contract, agreement or arrangement with any other individual or entity. 
 Section 11.11. Severability. If any term,
provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this
Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either
Party. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby
be consummated as originally contemplated to the fullest extent possible. 
 Section 11.12. Specific Performance.
The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement or to enforce specifically the performance of the terms and provisions hereof in any court set forth in Section 11.06, in addition to any other remedy to which they are entitled at law or in equity. 

[Remainder of page intentionally left blank] 

  
 22 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the date
first written above. 
  

			
	CELLECTIS S.A.
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	CALYXT, INC.
		
	By:	 	  

		 	Name:
		 	Title:

  
 23 

 Schedule A 

Licensed TALEN Mark 
  

											
	 Mark
	  	 Serial No.
	  	 Registration No.
	  	 Filing Date
	  	 Registration Date
	  	 Country

	 TALEN
	  	79/107519	  	4,729,507	  	October 27, 2011	  	May 5, 2015	  	U.S.

  
 A-1EX-10.6

 Exhibit 10.6 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
		 	 Internal University Use Only
 OTC
Agreement No.: A20150013
 OTC Case No.(s): 20130204

Document Revision Date: 2014-12-01

 UNIVERSITY OF MINNESOTA 

EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a
constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and
the Licensee agree that: 
 The Terms and Conditions of Exclusive Patent License attached hereto as Exhibit A (the “Terms and
Conditions”) are incorporated herein by reference in their entirety. In the event of a conflict between provisions of this Agreement and the Terms and Conditions, the provisions in this Agreement shall govern. Capitalized terms used in this
Agreement without definition shall have the meanings given to them in the Terms and Conditions. The section numbers used in the parentheses below correspond to the section numbers in the Terms and Conditions. 

1. Licensee (§1.7): Cellectis Plant Sciences a Corporation under the laws of the Delaware, having a place of business at 600 County Road
West, Suite 8 New Brighton, MN 55112, USA and its Affiliates. 
 2. Field(s) of Use (§1.2): All 

3. Territory (§1.15): Any country or territory where issued and unexpired Licensed Patents and/or Licensed Patent Applications exist. 

4. Effective Date (§2): Date of the last signature of the Agreement. 

5. Licensed Technology: 
 5.1
Licensed Patent: None 
  

			
	FORM OGC-401	  	Execution Copy
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

  
 1 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 5.2 Licensed Patent Applications (§1.4): 

[*****] 
 6. Patent-Related Expenses
(§§1.9 & 6.3): [Select one of the following] 
  

	 	☐	The Licensee has no obligation under this Agreement to reimburse the University for Patent-Related Expenses. 

  

	 	☒	The Licensee shall reimburse the University for Patent-Related Expenses incurred before and during the Term as provided in section 6.3 of the attached Terms and Conditions. Patent Related Expenses incurred before the
Term are [*****]. 

  

	 	☐	The Licensee shall reimburse the University for Patent-Related Expenses incurred during the Term as provided in section 6.3 of the Terms and Conditions. The Licensee shall have no obligation to reimburse the University
for Patent-Related Expenses incurred before the Effective Date. 

  

	 	☐	The Licensee shall reimburse the University for Patent-Related Expenses incurred before the Effective Date, payable as follows:
                    . The Licensee shall have no obligation to reimburse the University for Patent-Related Expenses during the Term.

 7. Sublicense Rights (§3.1.2): [Select one of the following] 

 

	 	☒	Yes 

  

	 	☐	No 

 8. Federal Government Rights (§3.2): [Select one of the following] 

 

	 	☒	Yes 

  

	 	☐	No 

  

			
	FORM OGC-401	  	Execution Copy
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 9. Performance Milestones (§5.1): The Licensee shall achieve the following milestones:

 [*****] 
 [*****] 

10. Payments (§6.1). All amounts are non-refundable, and payable as defined below or as specified in
the University’s invoice. 
 10.1 Upfront Payment: One Hundred Thirty Thousand dollars ($130,000.00), payable within ten
(10) business days after the Effective Date. 
 10.2 Annual License Fee:  

[*****] 
 10.3 Running Royalties
and Annual Minimums. 
 10.3.1 Intentionally left blank. 

10.3.2 Intentionally left blank. 

10.4   10.4.1 Sublicense Royalties. Intentionally left blank. 

10.4.2 Sublicense Revenues. Licensee shall pay the University [*****] of all Sublicense Revenues in accordance with the payment schedule set
forth below. 
 Within sixty (60) days after January 10 and July 10, each year during the Term and Post termination Period,
the Licensee shall deliver to the University a written report recounting the Sublicense Revenues (expressed in U.S. dollars). The Licensee shall deliver along with such sales reports its payment owed on all Sublicense Revenues by the Licensee during
such period. 
 10.5 Other Payments: None 

  

			
	FORM OGC-401	  	Execution Copy
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

  
 3 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 10.6 Equity: None 

10.7 Transfer Payment: [*****], payable as provided in section 12.5 of the Terms and Conditions. 

10.8 Administrative Handling Fee: [*****], payable as provided in subsection 8.1.1 of the Terms and Conditions. 

10.9 Interest Rate: [*****] per annum. 

10.10 Other: None 
 11. Licensee’s
Address for Notice (§12.13). Notices will be sent to the licensee at: 
  

			
		  	 Cellectis Plant Sciences
 8 rue de la Croix
Jarry,
 75013 Paris
 Attn: Chief Executive Officer

Facsimile No.: +33 18169 16 06
 Email:
Luc.mathis@cellectis.com

		
	With a copy to	  	 Cellectis, SA
 8 rue de la Croix Jarry,

75013 Paris
 Attn: General Counsel

Facsimile No.: +33 18169 16 06
 Email:
marie.bleuenn.terrier@cellectis.com

 12. Licensee’s Contact Person for Patent Prosecution Consultation (§4.2.1). The University will, as set
forth in this Agreement, communicate with the contact person named below with respect to patent prosecution and maintenance: (Upon ten (10) days prior written notice to the University, the Licensee may change the person designated below.) 

 

			
		  	 CELLECTIS SA
 Attn: Vice President

Intellectual Property
 8 rue de la Croix Jarry,

75013 Paris
 Attn: Chief Executive Officer

Facsimile No.: +33 (0) 18169 16 06
 Email:
sylvain.espinasse@cellectis.com

  

			
	FORM OGC-401	  	Execution Copy
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

  
 4 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 IN WITNESS THEREOF, the parties hereto have caused their duly authorized
representatives to execute this Agreement. 
  

									
	Regents of the University of Minnesota	 		 	Cellectis Plant Sciences, Inc.
					
	By:	 	 /s/ Richard Huebsch
	 		 	By:	 	 /s/ Luc Mathis

		 	Richard Huebsch	 		 	Name:	 	Luc Mathis
		 	Associate Director	 		 	Title:	 	CEO
		 	Office for Technology Commercialization	 		 		 	
					
	Date:	 	12-2-14	 		 	Date:	 	12-15-14

  

			
	FORM OGC-401	  	Execution Copy
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

  
 5 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 UNIVERSITY OF MINNESOTA 

EXHIBIT A 
 Terms and
Conditions 
 Exclusive Patent License Agreement 

These terms and conditions to the Exclusive Patent License Agreement (“Terms and Conditions”) govern the grant of license by Regents
of the University of Minnesota (“University”) to the Licensee identified in the Exclusive Patent License Agreement (the “EPLA”). These Terms and Conditions are incorporated by reference into the EPLA. All section references in
these Terms and Conditions refer to provisions in these Terms and Conditions unless explicitly stated otherwise. 
 1. Definitions. For
purposes of interpreting this Agreement, the following terms have the following meanings: 
 1.1 “Affiliate” means an entity that
controls the Licensee or the sublicensee, as the case may be, is controlled by the Licensee or sublicensee, or along with the Licensee or sublicensee, is under the common control of a Third Party. An entity shall be deemed to have control of the
controlled entity if it (i) owns, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities of the controlled entity, or (ii) has the right, power or authority, directly or indirectly, to direct or cause the
direction of the policy decisions of the controlled entity, whether by ownership of securities, by representation on the controlled entity’s governing body, by contract, or otherwise. 

1.2 “Commercial Sale” means a bona fide sale, use, lease, transfer or other disposition for value of a Licensed Product by the
Licensee or a sublicensee to a Third Party that is not an Affiliate of the Licensee. 
 1.3 “Field of Use” means the field(s) of
use described in section 2 of the EPLA. 
 1.4 “Licensed Patent” means the patent(s) described in section 5.1 of the EPLA, along
with any issued and unexpired patent(s) issued during the Term that arose out of a Licensed Patent Application. “Licensed Patent” also means any reissues or reexaminations of a Licensed Patent that contain one or more claims directed to
Licensed Technology. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-1 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 1.5 “Licensed Patent Application” means the pending patent application(s) described
in section 5.2 of the EPLA. “Licensed Patent Application” also means any related applications, including, continuations, continuations-in-part, and divisionals
of a Licensed Patent Application. 
 1.6 “Licensed Product” means any product or good in the Field of Use that is made by, made
for, sold, transferred, or otherwise disposed of by the Licensee or its sublicensees during the Term and the Post-termination Period and that, but for the granting of the rights set forth in this Agreement, would (i) infringe (including under
the doctrine of equivalents) one or more claims in a Licensed Patent; or (ii) is covered by one or more claims in a Licensed Patent Application, or any product or good that is made using a process or method that, but for the granting of rights
set forth in this Agreement, would (i) infringe (including under the doctrine of equivalents) one or more claims in a Licensed Patent; or (ii) is covered by one or more claims in a Licensed Patent Application. For purposes of this
Agreement, claims in a Licensed Patent Application are to be treated as if they were allowed as proposed. “Licensed Product” also means any service provided by or for the Licensee or its sublicensees, but for the granting of the rights set
forth in this Agreement, would (i) infringe (including under the doctrine of equivalents) one or more claims in a Licensed Patent; or (ii) is covered by one or more claims in a Licensed Patent Application. 

1.7 “Licensed Technology” means collectively the inventions claimed in each Licensed Patent and each Licensed Patent Application.

 1.8 “Licensee” means the entity identified in section 1 of the EPLA. 

1.9 “Patent-Related Expenses” means costs and expenses (including
out-of-pocket attorneys’ fees, patent agent fees and governmental filing fees) that the University incurs in prosecuting and maintaining the Licensed Technology.

 1.10 “Performance Milestone” means an act or event specified in section 5.1 and described in section 9 of the EPLA. 

1.11 “Post-termination Period” means the one hundred eighty (180) day period commencing on the date of termination or expiration
of the Term. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-2 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 1.12 “Sublicense Revenues” means all revenue, in whatever form but excluding
sublicense royalties, earned by the Licensee in consideration of its granting a Third Party a sublicense to make a Licensed Product including, without limitation, receipt of annual milestone attainment, sublicense issuance, maintenance or up-front payments, or technology access fee; and issuance of securities or real, personal or intangible property. 

1.13 “Territory” means the geographical area described in section 3 of the EPLA. 

1.14 “Third Party” means any party other than the University or Licensee or Affiliates’ Licensee. 

1.15 “Transfer Payment” means the payment to be made by the Licensee to the University specified in section 12.5 and described in
section 10 of the EPLA. 
 2. Term. The term of this Agreement commences on the Effective Date as defined in section 4 of the EPLA and, unless
terminated earlier as provided in section 8, expires on the date on which both no Licensed Patent is active in the Territory and no Licensed Patent Application is pending in the Territory (the “Term”). 

3. Grant of License. 
 3.1 The
Licensee’s Rights. 
 3.1.1 Subject to the terms and conditions of this Agreement, the University hereby grants to the
Licensee, and the Licensee hereby accepts, an exclusive license under the Licensed Technology, the Licensed Patents and the Licensed Patent Applications to make (including to have made on its behalf), use, offer to sell or sell (including to have
sold on its behalf), offer to lease or lease (including to have leased on its behalf), import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory. No provision of this Agreement is to be construed to
grant the Licensee, by implication, estoppel or otherwise, any rights (other than the rights expressly granted it in this Agreement) to the Licensed Technology, a Licensed Patent or Licensed Patent Application, or to any other University-owned
technology, patent applications, or patents. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-3 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 3.1.2 The Licensee shall not sublicense its rights under this Agreement,
unless otherwise provided in section 7 of the EPLA. If so provided, the Licensee may sublicense its rights under this Agreement only as follows: the Licensee shall deliver to the University a true, correct, and redacted copy (provided that all
rights, obligations, and financial provisions relating to the Licensed Patents and Licensed Patent Applications shall not be redacted) of the sublicense agreement or other agreement under which the Licensee purports or intends to grant such
sublicense rights within ten (10) days after the entry into force of such agreement. The Licensee shall not enter into such agreement if the terms of the agreement are inconsistent in any respect with the terms of this Agreement, including
without limitation, sections 5.2—5.5, 6.5, 8.3, 9.5, 10.4, and 11.3. Any sublicense made in violation of this subsection is void and constitutes an event of default under subsection 8.1.1. 

For the avoidance of doubt, the Licensee may grant to sublicensees the right to grant further sublicenses to use the Licensed Technology but
only for the purpose of breeding and/or manufacturing and/or selling Licensed Products. 
 3.2 The United States Government’s Rights. If
the University indicated in section 8 of the EPLA that the United States federal government funded the development, in whole or in part, of the Licensed Technology, then, (i) the federal government may have certain rights in and to the Licensed
Technology as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal Regulations. (ii) the parties’ rights and obligations with
respect to the Licensed Technology, including the grant of license set forth in subsection 3.1.1, are subject to the applicable terms of these laws and regulations. 

3.3 The University’s Rights. The University retains an irrevocable, world-wide, royalty-free,
non-exclusive right to use the licensed Technology for teaching, research and educational purposes. The University shall have the right to sublicense its rights under this section to one or more non-profit academic or research institutions. 
 4. Applications and Patents. 

4.1 Pre-EPLA Patent Filings. The Licensee acknowledges that it has reviewed each Licensed Patent and
each Licensed Patent Application and that it will not dispute the inventorship, validity, or enforceability of any of the claims made in a Licensed Patent or a Licensed Patent Application. The Licensee further represents that up to the Effective
Date, it has 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-4 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 
not and does not manufacture, have manufactured, offer to sell, sell, offer to lease, lease, or import (a) any product or good that infringes (including under the doctrine of equivalents) a
claim in any Licensed Patent or Licensed Patent Application, or (b) any product or good that is made using a process or machine that infringes (including under the doctrine of equivalents) a claim in a Licensed Patent or Licensed Patent
Application. 
 4.2 Patent Application Filings during the Term of this Agreement. 

4.2.1 The University, in consultation with the Licensee, shall determine in which countries patent application(s) will be filed
and prosecuted with respect to the Licensed Technology. The University shall retain counsel of its choice to file and prosecute such patent applications. The University shall inform the Licensee of the status of the prosecution of the patent
application, including delivering to the Licensee pertinent notices, written and oral communications with governmental officials, and documents, and shall consult with the Licensee on the prosecution of the patent application. The Licensee shall
cooperate with the University in the filing and prosecution of all patent applications with respect to the Licensed Technology. In furtherance of the foregoing, the Licensee shall notify the University, in writing, of the individual whom the
Licensee has designated to consult and cooperate as provided in this subsection and is identified in section 12 of the EPLA. The Contact Person shall respond to the University’s request for consultation and cooperation on a pending matter
within five business days or sooner as may be required under the circumstances. If the Contact Person fails to respond in such time period, the University, exercising its own judgment and discretion, may respond to the matter as it deems
appropriate. Except as provided in subsection 4.2.2, the Licensee shall reimburse the University for all Patent-Related Expenses as provided in section 6.3 and in section 6 of the EPLA. Additionally, Licensee shall reimburse the University for
Patent Related Expenses for prioritized patent examination (Track One) if the University, after consultation with Licensee, decides to pursue Track One. 

4.2.2 The grant of license in section 3.1 and the definition of Territory in section 1.16 shall not extend to or include any
country in which licensee elects, in writing to the University, not to pay or reimburse the payment of the cost, in whole or in part, to seek or maintain intellectual property protection. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-5 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 4.2.3 No provision of this Agreement limits, conditions, or otherwise affects
the University’s right to prosecute a patent application with respect to the Licensed Technology in any country. The University retains the sole and exclusive right to file or otherwise prosecute a patent application with respect to the
Licensed Technology. In no event shall the Licensee file a patent application with respect to the Licensed Technology. The Licensee shall cooperate with the University in the filing and prosecution of all patent applications with respect to the
Licensed Technology. 
 4.3 Rights in the Licensed Patents and Licensed Patent Applications. No provision of this Agreement grants the
Licensee any rights, titles, or interests (except for the grant of license in subsection 3.1.1) in the Licensed Patents or Licensed Patent Applications, notwithstanding the Licensee’s payment of all or any portion of the patent prosecution,
maintenance, and related costs. 
 5. Commercialization. 

5.1 Commercialization and Performance Milestones. The Licensee shall use its commercially reasonable efforts, consistent with sound and
reasonable business practices and judgment, to commercialize the Licensed Technology and to manufacture and offer to sell and sell Licensed Products as soon as practicable and to maximize sales thereof. The Licensee shall perform, or shall cause to
happen or be performed, as the case may be, all the performance milestones described in section 9 of the EPLA. 
 In case of
non-achievement by the Licensee of the Performance Milestone indicated in the section 9 of the EPLA, the Parties will meet at the University of Minnesota or by telephone to discuss this Agreement. 

5.2 Covenants Regarding the Manufacture of Licensed Products. The Licensee hereby covenants and agrees that (i) the manufacture, use,
sale, or transfer of Licensed Products shall comply with all applicable federal and state laws, including all federal export laws and regulations; and (ii) it will make commercially reasonable efforts such that the Licensed Products shall not
be defective in design or manufacture. The Licensee hereby further covenants and agrees that, pursuant to 35 United States Code Section 204, it shall, and it shall cause each sublicensee, to substantially manufacture in the United States of
America all products embodying or produced through the use of an invention that is subject to the rights of the federal government of the United States of America, provided that the University will use reasonable efforts (i.e. contact the competent
governmental authority, by phone call and e-mail, with Licensee administrative support) to obtain a waiver on behalf of Licensee. If the University anticipates that its efforts will exceed two hours of administrative time, the University will notify
Licensee and will provide further efforts at Licensee’s expense to the extent administrative support is available. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-6 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 5.3 Export and Regulatory Compliance. The Licensee understands that the Arms Export Control
Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR,) and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise
the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (i) ITAR and EAR product/service/data-specific requirements; (ii) ITAR and EAR ultimate
destination-specific requirements; (iii) ITAR and EAR end user-specific requirements; (iv) Foreign Corrupt Practices Act; and (v) antiboycott laws and regulations. The Licensee shall comply with all then-current applicable export laws
and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Products (including any associated products, items, articles, computer software, media, services, technical data, and other
information). The Licensee certifies that it shall not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed Products (including any
associated products, items, articles, computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations. The Licensee shall include an
appropriate provision in its agreements with its authorized sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations. 

5.4 Commercialization Reports. Throughout the Term and during the Post- termination Period, and within thirty (30) days of the date
specified in the schedule set forth in section 10 of the EPLA, the Licensee shall deliver to the University written reports of the Licensee’s and sublicensees’ (or any further sublicensees’) efforts and plans to commercialize the
Licensed Technology and to manufacture, offer to sell, or sell Licensed Products. 
 5.5 Use of the University’s Name and Trademarks or
the Names of University Faculty, Staff, or Students. No provision of this Agreement grants the Licensee or sublicensee any right or license to use the name, logo, or any marks owned by or associated with the University or the names, or identities of
any member of the faculty, staff, or student body of the University. The Licensee shall not use and shall not permit a sublicensee to use any such logos, marks, names, or identities without the University’s and, as the case may be, such
member’s prior written approval. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-7 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 5.6 Governmental Markings. 

5.6.1 The Licensee may mark all Licensed Products, where feasible, with patent notice appropriate under Title 35, United States
Code. 
 5.6.2 The Licensee is responsible for obtaining all necessary governmental approvals for the development,
production, distribution, sale, and use of any Licensed Product, at the Licensee’s expense, including, without limitation, any safety studies. The Licensee is responsible for including with the Licensed Product any warning labels, packaging and
instructions as to the use and the quality control for any Licensed Product. 
 5.6.3 The Licensee agrees to register this
Agreement with any foreign governmental agency that requires such registration, and the Licensee shall pay all costs and legal fees in connection with such registration. The Licensee shall comply with all foreign laws affecting this Agreement or the
sale of licensed Products. 
 6. Payments, Reimbursements, Reports, and Records. 

6.1 Payments. The Licensee shall pay all amounts due under this Agreement by check (payable to the “Regents of the University of
Minnesota” and sent to the address specified in section 12.13), wire transfer, or any other mutually agreed-upon method of payment, within thirty (30) days following the receipt by the Licensee of the University’s relevant and
undisputed invoice. 
 6.2 Interest. All amounts due under this Agreement shall bear interest as provided in section 10.10 of the EPLA on the
entire unpaid balance computed from the due date until the amount is paid. 
 6.3 Reimbursement of Patent-Related Expenses. The Licensee
shall pay invoices for Patent-Related Expenses under this Agreement within thirty (30) days of its receipt of the University’s invoice. With respect to each invoice, the University shall use reasonable efforts to specify the date on which
the Patent-Related Expense was incurred and the purpose of the expense (including, as applicable, a summary of patent attorney services giving rise to the expense); provided, however, the University is not required to disclose to the Licensee any
information that is protected by the University’s attorney-client privilege. Patent-Related Expenses incurred as of the Effective Date are set forth in section 6 of the EPLA. The University reserves the right to require that Licensee provide
and maintain a reasonable advance deposit with the University or some other form of security to ensure payment of Patent-Related Expenses. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-8 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 6.4 Records Retention and Audit Rights. 

6.4.1 Throughout the Term and the Post-termination Period and for five (5) years thereafter, the Licensee, at its expense,
shall keep and maintain and shall cause each sublicensee and each non-affiliated Third Party that manufactures, sells, leases, or otherwise disposes of Licensed Products on behalf of the Licensee to keep and
maintain complete and accurate records of all sales, leases, and other dispositions of Licensed Products during the Term and the Post-termination Period and all other records related to this Agreement. 

6.4.2 In connection with an audit, the Licensee, upon written request, shall deliver to the University and its representatives
true, correct and complete copies of all documents and materials (including electronic records) reasonably relevant to the Licensee’s and sublicensees’ performance of this Agreement, including, without limitation, all sublicenses granted.

 6.4.3 To determine the Licensee’s compliance with the terms of this Agreement, the University, at its expense (except
as set forth in this subsection), may inspect and audit the Licensee’s records referred to in subsection 6.5.1 at the Licensee’s address as set forth in this Agreement or such other location(s) as the parties mutually agree during the
Licensee’s normal business hours. The Licensee shall cooperate in the audit, including providing at no cost, commodious space in the Licensee’s place of business for the auditor. The Licensee shall reimburse the University for all its out-of-pocket expenses to inspect and audit such records if the University, in accordance with the results of such inspection and audit, determines that the Licensee has underpaid amounts owed to the University by
at least [*****], whichever is smaller, in a reporting period. The Licensee shall cause each sublicensee and each non-affiliated Third Party that manufactures, sells, leases, or otherwise disposes of Licensed
Products on behalf of the Licensee to grant the University a right to inspect and audit the sublicensee’s or Third Party’s records substantially similar to the rights granted the University in this subsection, if requested by University,
but no more frequently than once every two years. In connection with, and 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-9 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 
before the commencement of, an audit, if the Licensee requests in writing to the University, then prior to conducting such audit, the Licensee, the University and the auditor must enter into an
agreement prohibiting the auditor and the University from disclosing the Licensee’s nonpublic, proprietary information to any Third Party without the Licensee’s prior written consent; provided, however, that consistent with generally
accepted auditing standards and the auditor’s professional judgment, the auditor may disclose such information to the University and its agents, counsel, or consultants. The Licensee acknowledges that such an agreement is adequate to protect
its legitimate interests, and the parties agree that there shall be no additional nondisclosure agreement demanded as a condition to the commencement of an audit and the University’s exercising its rights under this subsection. 

6.5 Currency and Checks. All computations and payments made under this Agreement shall be in United States dollars. To determine the dollar
value of transactions conducted in non-United States dollar currencies, the parties shall use the exchange rate for the currency into dollars as reported in the Wall Street Journal as the New York
foreign exchange mid-range rate on the last business day of the month in which the transaction occurred. 
 7.
Infringement. 
 7.1 If a party learns of substantial, credible evidence that a Third Party is making, using, or selling a product in the
Field of Use in the Territory that infringes a Licensed Patent, such party shall promptly notify the other party in writing of the possible infringement and in such notice describe in detail the information suggesting infringement of the Licensed
Patent. Prior to commencing any action to enforce a Licensed Patent, the parties shall enter into good faith negotiations on the desirability of bringing suit, the parties to the action, the selection of counsel, and such other matters as the
parties may agree to discuss. No provision of this Agreement limits, conditions, or otherwise affects a party’s statutory and common-law rights to commence an action to enforce a Licensed Patent. In any
such action, the parties agree to cooperate fully with each other and will use reasonable efforts to permit access to relevant personnel, records, papers, information, samples and specimens during regular business hours. Any amounts recovered (less
amounts actually paid for reasonable attorney’s fees and legal expenses) by Licensee in any such action or settlement that constitute compensation for lost profits or sales will be considered subject to the royalty rate in subsection 10.3.1 of
the EPLA. All other amounts recovered (less amounts actually paid for reasonable attorney’s fees and legal expenses) by Licensee in such action or settlement shall be considered subject to the rate for Sublicense Revenues in subsection 10.4.2
of the EPLA. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-10 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 7.2. If any suit, action or proceeding is brought or commenced against the Licensee alleging
the infringement of a patent or other intellectual property right owned by a Third Party by reason of the manufacture, use or sale of Licensed Products, the Licensee shall give the University prompt notice thereof. If the validity of a Licensed
Patent is questioned in such suit, action or proceeding, the Licensee shall have no right to make any settlement or compromise which affects the scope, validity, enforceability or otherwise the Licensed Patent without the University’s prior
written approval. University shall provide reasonable assistance to Licensee in the defense of the Licensed Patent at Licensee’s expense. 
 8.
Termination. 
 8.1. By the University. 

8.1.1 If the Licensee breaches or fails to perform one or more of its obligations under this Agreement, the University may
deliver a written notice of default to the Licensee. Without further action by a party, this Agreement shall terminate if (a) the University has not been paid the full amount of the Administrative Handling Fee set forth in section 10.9 of the
EPLA, and (b) the default has not been cured in full within either sixty (60) days after the delivery to the Licensee of the notice of default if the default relates to a payment or reimbursement obligation under this Agreement, or ninety
(90) days after the delivery to the Licensee of the notice of default if the default relates to any other matter. 

8.1.2 The University may terminate this Agreement by delivering to the Licensee a written notice of termination at least ten
(10) days before the date of termination if the Licensee (i) becomes insolvent; (ii) voluntarily files or has filed against it a petition under applicable bankruptcy or insolvency laws that the Licensee fails to have released within
thirty (30) days after filing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee, custodian, or similar agent is appointed; or (iv) makes a general assignment for the
benefit of creditors. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-11 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 8.1.3 The University may terminate this Agreement immediately by delivering
to the Licensee a written notice of termination if the Licensee or its agents or representatives commences or maintains an action in any court of competent jurisdiction or a proceeding before any governmental agency asserting or alleging, in any
respect, the invalidity or unenforceability of any of the Licensed Technology. The Licensee shall notify the University, in writing, at least thirty (30) days prior to the commencement of any such action or the institution of any such
proceeding. 
 8.2 By the Licensee. 
 8.2.1 If
the University breaches or fails to perform one or more of its duties under this Agreement, the Licensee may deliver to the University a written notice of default. The Licensee may terminate this Agreement by delivering to the University a written
notice of termination if the default has not cured in full within ninety (90) days of the delivery to the University of the notice of default. 
 8.2.2
The Licensee may terminate this Agreement at any time by giving sixty (60) days written notice to the University. 
 8.3 Effect of
termination. 
 8.3.1 Notwithstanding anything contained herein, in case of termination of this Agreement by the University pursuant to the terms herein, any
sublicensee (each an “Exclusive Sublicensee” as further defined hereinafter) that has been granted exclusive rights under the Licensed Technology by Licensee, within a certain field (the “Exclusive Field”), shall have the right
to substitute itself to licensee under this Agreement with respect to such Exclusive Field; provided Licensee has delivered to University written notice of the existence of the Exclusive Sublicensee prior to receipt of University’s notice of
termination under Section 8 of the terms and Conditions, except that no prior written notice is required if such sublicensee became an Exclusive Sublicensee as a result of any change in the control of Licensee’s Affiliates. For any
avoidance of doubt, (i) the terms and conditions applicable to Licensee with respect to such an Exclusive Field shall survive any termination and apply to such Exclusive Sublicensee which will be substituted under the Agreement; and
(ii) substitution of an Exclusive Sublicensee with respect to rights and obligations of Licensee will not impact Licensee’s liability, rights and obligations accrued to Licensee up to the date of substitution. An “Exclusive
Sublicensee” means any sublicensee that has been granted exclusive rights within an Exclusive Field by Licensee under the Licensed Technology prior to Licensee’s receipt of University’s notice of termination under Section 8 of
the Terms and Conditions. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-12 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 8.3.2 Further, in addition to the rights conferred upon Exclusive Sublicensees in the previous paragraph,
other sublicensees, upon termination of the Agreement by the University or by the Licensee, will have the right to obtain a direct license from the University (comparable in scope, grant and the same financial terms as the sublicense then held by
such sublicensee with respect to the Licensed Technology) under the terms and conditions (other than with respect to the scope, grant and financial terms) of this Agreement; provided (i) the University consents to providing such a direct
license, which consent shall not be unreasonably withheld, (ii) any such sublicensee is not then in default of its contractual obligations under the relevant sublicense agreement, (iii) any such sublicensee provides the University written
notice of its desire to obtain a direct license within thirty (30) days following termination of this Agreement, and (iv) such sublicensee obtained a sublicense from Cellectis or its Affiliates before Licensee received a notice of
termination pursuant to Section 8 of the Terms and Conditions. 
 8.3.3 Post-termination Period. The Licensee shall not use, or permit others to use,
the Licensed Technology or manufacture or have manufactured Licensed Products after this Agreement terminates. If the Licensee terminates this Agreement under section 8.2, the Licensee may continue to offer to sell and sell, offer to lease and
lease, and otherwise offer to dispose of or dispose of Licensed Products in the Territory that were manufactured before such termination. The Commercial Sales of Licensed Products during the Post-termination Period shall be governed by the terms of
this Agreement, including the obligation to pay royalties on such Commercial Sales as provided in this Agreement. If the University terminates this Agreement under section 8.1, after the date of termination, the Licensee shall not offer to sell or
sell, offer to lease or lease, or otherwise offer to dispose of or dispose of a Licensed Product in the Territory. 
 8.3.4 In case of termination, as
mentioned in Section 8.2.2 of the Terms and Conditions (i) Licensee will pay to the University the amounts due under Section 10.2 and 10.4.2, within thirty (30) days by of the termination date under Section 8.2.2; and
(ii) Licensee will pay the University the Annual License Fee for the succeeding year, within thirty (30) days of the termination date under Section 8.2.2. 

9.Release, Indemnification, and Insurance. 

9.1 The Licensee’s Release. For itself and its employees, the Licensee hereby releases the University and its regents, employees, and
agents forever from any and all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses) relating to or arising out of the manufacture, use, lease, sale, or other
disposition of a Licensed Product. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-13 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 9.2 The Licensee’s Indemnification. Throughout the Term and thereafter, the Licensee
shall indemnify, defend, and hold the University and its regents, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses),
relating to or arising out of the Licensee’s exercises or attempt to exercise any of the rights or Licenses granted it under this Agreement, including without limitation, the manufacture, use, lease, sale, or other disposition of a licensed
Product or the licensee’s breach of any term of this Agreement. 
 9.3 The University’s Indemnification. Subject to the limitations
on liability set forth in section 11, throughout the Term and thereafter, the University shall indemnify, defend, and hold the Licensee and its directors, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages,
losses, or expenses (including reasonable attorneys’ and investigative expenses) relating to or arising out of the University’s breach of any term of this Agreement. 

9.4 The Licensee’s Insurance. 

9.4.1 Throughout the Term, or during such other period as the parties agree in writing, the Licensee shall maintain, and shall
cause each sublicensee to maintain, in full force and effect comprehensive general liability (“CGL”) insurance, with single claim limits acceptable to the University. Such insurance policy shall include coverage for claims that may be
asserted by the University against the licensee under section 9.2 and for claims by a Third Party against the Licensee or the University arising out of the purchase or use of a Licensed Product. Such insurance policy must (i) name the
University as an additional insured if the University so requests in writing and (ii) require the insurer to deliver written notice to the University at the address set forth in section 12.13, at least thirty (30) days before the
termination of the policy. Upon receipt of the University’s written request, the Licensee shall deliver to the University a copy of the certificate of insurance for such policy. 

9.4.2 The provisions of subsection 9.4.1 do not apply if the University agrees in writing to accept the Licensee’s or a
sublicensee’s, as the case may be, self-insurance plan as adequate insurance. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-14 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 9.5 Sublicensees - Release. The Licensee shall cause each sublicensee to grant the University
a release from liabilities substantially similar to the release granted in favor of the University in section 9.1. 
 10. Warranties. 

10.1 Authority. Each party represents and warrants to the other party that it has full corporate power and authority to execute, deliver, and
perform this Agreement, and that no other corporate proceedings by such party are necessary to authorize the party’s execution or delivery of this Agreement. 

10.2 The University represents and warrants that (i) it is the sole owner of the Licensed Patent Application; (ii) the
University’s Office for Technology Commercialization has not entered into an agreement granting to a Third Party the right to use the Licensed Technology for commercial purposes. 

10.3 Disclaimers. 

10.3.1 EXCEPT FOR THE EXPRESS WARRANTY SET FORTH ABOVE IN SECTION 10.1, THE UNIVERSITY DISCLAIMS AND EXCLUDES ALL
WARRANTIES, EXPRESS AND IMPLIED, CONCERNING THE LICENSED TECHNOLOGY, EACH LICENSED PATENT, EACH LICENSED PATENT APPLICATION, AND EACH LICENSED PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
NON-INFRINGEMENT, OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE. 

10.3.2 The University expressly disclaims any warranties concerning and makes no representations: 

 

	 	(i)	that the Licensed Patent Applications will be allowed or granted or that a patent will issue from any Licensed Patent Application; 

  

	 	(ii)	concerning the validity, enforceability, interpretation of claims or scope of any Licensed Patent; or 

  

	 	(iii)	that the exercise of the rights or licenses granted to the Licensee under this Agreement will not infringe a Third Party’s patent or violate its intellectual property rights. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-15 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 10.4 Sublicensees - Warranties. The Licensee shall cause each sublicensee to give the
University warranties and disclaimers and exclusions of warranties substantially similar to the warranty and disclaimers and exclusions of warranties in favor of the University in section 10.1 and subsections 10.3.1 and 10.3.2. 

11. Damages. 
 11.1 Remedy Limitation.
EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, THE UNIVERSITY SHALL NOT BE LIABLE FOR (A) PERSONAL INJURY OR PROPERTY DAMAGES (EXCEPT TO THE EXTENT OF THE UNIVERSITY’S WILLFUL, WANTON, OR INTENTIONAL ACTS) OR
(B) LOST PROFITS, LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER RELIANCE OR EXPECTANCY, DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND. 

11.2 Damage Cap. THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT OF
PAYMENTS PAID TO THE UNIVERSITY UNDER SECTION 6.4 IN THE SIX (6) MONTHS IMMEDIATELY PRECEDING THE COMMENCEMENT OF ANY SUIT OR ACTION. THIS LIMITATION APPLIES TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE. 

11.3 Sublicensees - Damages. The Licensee shall cause each sublicensee to agree to limitations of remedies and damages substantially similar to
the limitations of remedies and damages set forth in sections 11.1 and 11.2. 
 12. General Terms 

12.1 Access to University Information. 

12.1.1 Data Practices Act. The parties acknowledge that the University is subject to the terms and provisions of the Minnesota
Government Data Practices Act, Minnesota Statutes §13.01 et seq. (the “Act”), and that the Act requires, with certain exceptions, the University to permit the public to inspect and copy any information that the University collects,
creates, receives, maintains, or disseminates. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-16 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 12.1.2 Confidentiality. To the extent permitted by law, including as provided
in the Act, the University shall hold in confidence and disclose only to University employees, agents and contractors who need to know the reports described in section 6.4 and the records inspected in accordance with section 6.5 of the Terms and
Conditions. No provision of this Agreement is to be construed to further prohibit, limit, or condition the University’s right to use and disclose any information in connection with enforcing this Agreement, in court or elsewhere. 

12.2 Amendment and Waiver. The Agreement may be amended from time to time only by a written instrument signed by the parties. No term or
provision of this Agreement may be waived and no breach excused unless such waiver or consent is in writing and signed by the party claimed to have waived or consented. No waiver of a breach is to be deemed a waiver of a different or subsequent
breach. 
 12.3 Applicable law and Forum Selection. The internal laws of the state of Minnesota, without giving effect to its conflict of
laws principles, govern the validity, construction, and enforceability of this Agreement. A suit, claim, or other action to enforce the terms of this Agreement may be brought only in the state courts of Hennepin County, Minnesota. The Licensee
hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over the Licensee or its assets and property. 

12.4 Assignment and Sublicense. Except as permitted under subsection 3.1.2 and section 12.5 of the Terms and Conditions, the Licensee shall not
assign or sublicense its interest or delegate its duties under this Agreement. Any assignment, sublicense, or delegation attempted to be made in violation of this section is void. Absent the consent of all the parties, an assignment or delegation
will not release the assigning or delegating party from its obligations. The Agreement inures to the benefit of the licensee and the University and their respective permitted sublicensees and trustees. 

12.5 Change of Control. Notwithstanding section 12.4, the Licensee, without the prior approval of the University, may assign all, but no less
than all, its rights and delegate all its duties under this Agreement to another if (i) the Licensee delivers to the University written notice of the proposed assignment (along with pertinent information about the terms of the assignment and
assignee) at least thirty (30) days before the effective date of the event described in part (iii) of this paragraph, (ii) pay to the University the Transfer Payment prior to the effective date of the event described in part
(iii) of this paragraph, and (iii) the assignment is made as a part of and in 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-17 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 
connection with (a) the sale by the Licensee of all or substantially all of its assets to a single purchaser, (b) the sale, transfer, or exchange by the shareholders, partners, or
equity owners of the licensee of a majority interest in the Licensee to a single purchaser, or (c) the merger of the Licensee into another corporation or other business entity that is not an Affiliate. Any assignment attempted to be made or
made in violation of this subsection is void. 
 12.6 Collection Costs and Attorneys’ Fees. If a party fails to perform an obligation or
otherwise breaches one or more of the terms of this Agreement, the other party may recover from the non-performing breaching party all its reasonable costs (including actual attorneys’ and investigative
fees) to enforce the terms of this Agreement. 
 12.7 Consent and Approvals. Except as otherwise expressly provided, in order to be
effective, all consents or approvals required under this Agreement must be in writing. 
 12.8 Construction. The headings preceding and
labeling the sections of this Agreement are for the purpose of identification only and are not to be employed or used for the purpose of construction or interpretation of any portion of the EPLA. As used herein and where necessary, the singular
includes the plural and vice versa, and masculine, feminine, and neuter expressions are interchangeable. 
 12.9 Enforceability. If a court
of competent jurisdiction adjudges a provision of this Agreement to be unenforceable, invalid, or void, such determination is not to be construed as impairing the enforceability of any of the remaining provisions hereof and such provisions will
remain in full force and effect. 
 12.10 Entire Agreement. The parties intend this Agreement (including all attachments, exhibits, and
amendments hereto) to be the final and binding expression of their contract and agreement and the complete and exclusive statement of the terms thereof. The Agreement cancels, supersedes, and revokes all prior negotiations, representations and
agreements among the parties, whether oral or written, relating to the subject matter of this Agreement. 
 12.11 Language and Currency.
Unless otherwise expressly provided in this Agreement and in order to be effective, all notices, reports, and other documents and instruments that a party elects or is required to deliver to the other party must be in English, and all notices,
reports, and other documents and instruments detailing revenues and earned under this Agreement or expenses chargeable to a party must be United States dollar denominated. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-18 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 12.12 No Third-Party Beneficiaries. No provision of this Agreement, express or implied, is
intended to confer upon any person other than the parties to this Agreement and their Affiliates any rights, remedies, obligations, or liabilities hereunder. No sublicensee may enforce or seek damages under this Agreement. 

12.13 Notices. In order to be effective, all notices, requests, and other communications that a party is required or elects to deliver must be
in writing and must be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid,
return receipt requested, to the other party at its address set forth below or to such other address as such party may designate by notice given under this section: 

If to the University:     University of Minnesota 

Office of Technology Commercialization 

200 Oak Street, SE Suite 280 

Minneapolis, MN 55455 
 Phone:
612.624.0550 
 For notices
sent                    University of Minnesota 
 under
section 8,                     Office of the General Counsel 

with a copy to:                      Attn:
Transactional Law Services 

                          
                   360 McNamara Alumni Center 

                          
                   200 Oak Street S.E. 

                          
                   Minneapolis, MN 55455-2006 

                          
                   Facsimile No.: 612.626.9624 

                          
                   E-mail: contracts@mail.ogc.umn.edu 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-19 

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 If to the Licensee: As indicated in section 11 of the EPL. 

12.14 Relationship of Parties. In entering into, and performing their duties under this Agreement, the parties are acting as independent
contractors and independent employers. No provision of this Agreement creates or is to be construed as creating a partnership, joint venture, or agency relationship between the parties. No party has the authority to act for or bind the other party
in any respect. 
 12.15 Security Interest. In no event may the Licensee grant, or permit any person to assert or perfect, a security
interest in the Licensee’s rights under this Agreement. 
 12.16 Survival. Immediately upon the termination or expiration of this
Agreement, except for certain rights granted for the Post-termination Period, all the Licensee’s rights under this Agreement terminate; provided, however, the Licensee’s obligations that have accrued before the effective date of
termination or expiration (e.g., the obligation to report and make payments on sales, leases, or dispositions of Licensed Products and to reimburse the University for costs) and the obligations specified in section 6.1 survive. The obligations and
rights set forth in sections 6.4 and 8.3 and sections 9, 10, and 11 also survive the termination or expiration of this Agreement. 

  

			
	FORM OGC-401	  	
	Exclusive Patent License Agreement	  	
	Form Date: 12.18.01	  	
	Revision Date: 03/04/2014	  	

 A-20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]